Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure

1996 ◽  
Vol 97 (6) ◽  
pp. 1350-1355 ◽  
Author(s):  
Margherita Tomassini ◽  
Laura Magrini ◽  
Guido De Petrillo ◽  
Emilio Adriani ◽  
Stefano Bonini ◽  
...  
Author(s):  
Kouichi Ikai ◽  
Atsuhiko Ogino ◽  
Ikuko Furukawa ◽  
Motoaki Ozaki ◽  
Mayumi Fujita ◽  
...  

1997 ◽  
Vol 22 (2) ◽  
pp. 100-105 ◽  
Author(s):  
Y. OHASHI ◽  
Y. NAKAI ◽  
Y. KAKINOKI ◽  
Y. OHNO ◽  
H. OKAMOTO ◽  
...  

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Kawa Amin ◽  
Sulaf Mosa Issa ◽  
Kosar Mohammad Ali ◽  
Muaid Ismiel Aziz ◽  
Huner Mohamed Hama Amieen ◽  
...  

Abstract Background The aim was to determine the level of inflammatory cytokines, eosinophil cationic protein and IgE in allergic rhinitis (AR) patients. Subjects and methods Blood samples were taken from 88 AR patients and 88 healthy controls (HC). Each sample was analysed for eosinophil counts by flow cytometry, IgE by ECLIA, ECP, IL-17, and IL-33 by using ELISA test. Results There was no significant difference between AR patients and the control group in age and gender. Levels of eosinophils, IgE, ECP, IL-17, IL-33 and the total symptom scores were significantly higher in AR patients than the HC (P = 0.0001). Serum ECP correlated with IL-17 (P = 0.041, r = 0.42), IL-33 (P = 0.0001, r = 080), and IgE levels (P = 0.017, r = 0.45) in the R patients. There was no correlation between IL-17 and IL-33. There was a correlation between symptom scores and eosinophils (P = 0.026, r = 0.52), and IgE (P = 0.001, r = 0.60) in the patients. No correlation was observed between symptom scores and ECP, IL-17, and IL-33 in the AR patient. Conclusions Patients with AR have significant higher serum levels of ECP, IL-17, and IL-33 than healthy controls. This indicates that these markers could be used to in order to diagnose AR and to monitor disease. Inhibitory molecules to IL-17 and IL-33 may be considered as novel treatment strategies.


Acta Tropica ◽  
1996 ◽  
Vol 62 (3) ◽  
pp. 171-182 ◽  
Author(s):  
F.W. Tischendorf ◽  
N.W. Brattig ◽  
D.W. Büttner ◽  
A. Pieper ◽  
M. Lintzel

1997 ◽  
Vol 106 (10) ◽  
pp. 848-853 ◽  
Author(s):  
Yoshiaki Nakai ◽  
Hirokazu Sakamoto ◽  
Yoshihiro Ohashi ◽  
Yasushi Kakinoki ◽  
Akifumi Kato ◽  
...  

Eosinophil cationic protein (ECP) levels in the serum of clotted blood could reflect the rate of activation of circulating eosinophils. We investigated the serum ECP levels in patients with perennial allergic rhinitis, with special reference to the effect of immunotherapy on the serum ECP levels. Serum ECP levels in untreated patients with perennial allergic rhinitis are significantly higher than those of nonatopic volunteers. Therefore, this elevation in the untreated patients represents an ongoing inflammation occurring in allergic rhinitis. The mean serum ECP level of a 1-year immunotherapy group was significantly higher than that of the nonatopic group, and was not different from that of the untreated group. In contrast, the mean serum ECP level in patients who had more than 2 years of immunotherapy was significantly lower than that of the untreated group, and was not different from that of the nonatopic group. Additionally, serum ECP levels were significantly correlated with the duration of immunotherapy. These findings suggest that activation of circulating eosinophils decreases gradually during immunotherapy, but this inhibition becomes apparent only after 2 years of immunotherapy. The control of circulating eosinophil activation might be one of the important working mechanisms behind the clinical effect of immunotherapy.


Sign in / Sign up

Export Citation Format

Share Document